SOPHiA GENETICS

SOPHiA GENETICS EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of SOPHiA GENETICS (SOPH) as of Oct 21, 2026 is -7.82. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -5.32 — a change of 46.95% (lower).

EV/FCF

-7.82

YoY

46.95%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of SOPHiA GENETICS is 2025 -7.82 . EV/FCF (Enterprise Value to Free Cash Flow) of SOPHiA GENETICS was 2024 -5.32 . It decreases by 46.95% lower compared to the previous year.

The SOPHiA GENETICS EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-8.98 USD
Jan 1, 2020
-6.63 USD
Jan 1, 2021
-1.07 USD
Jan 1, 2022
-1.98 USD
Jan 1, 2023
-3.75 USD
Jan 1, 2024
-5.32 USD
Jan 1, 2025
-7.82 USD
The SOPHiA GENETICS EV/FCF history
YEAREV/FCFYoY
-7.82+46.95%
-5.32+41.79%
-3.75+89.15%
-1.98+84.80%
-1.07-83.79%
-6.63-26.21%
-8.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SOPHiA GENETICS Stock analysis

What does SOPHiA GENETICS do? Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. SOPHiA GENETICS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SOPHiA GENETICS stock

EV/FCF (Enterprise Value to Free Cash Flow) of SOPHiA GENETICS is -7.82 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of SOPHiA GENETICS changed from -5.32 to -7.82, representing a 46.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) SOPHiA GENETICS since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s SOPHiA GENETICS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SOPHiA GENETICS

All Key Metrics — SOPHiA GENETICS